Trial Search Results
Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab
Patients with diabetic macular edema who were switched to aflibercept after having been treated with bevacizumab or ranibizumab were retrospectively reviewed to assess for visual acuity and anatomic outcomes.
Stanford is currently not accepting patients for this trial.
- Drug: Intravitreal Injection of Aflibercept
Inclusion Criteria: Those patients with diabetic macular edema switched to aflibercept from
bevacizumab and/or ranibizumab -
Exclusion Criteria: None
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study